Genentech Raises Tarceva Price
This article was originally published in The Pink Sheet Daily
Firm says 8% hike will support further R&D, not impact patient access.
You may also be interested in...
Program similar to Amgen’s for Vectibix.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.